

No. 41

August 9, 2013 (Erh/Sel)

Anogenital cancer: How cancer cells benefit from the absence of a signaling molecule

An infection with human papillomaviruses (HPV) can cause not only cervical cancer but also other types of anogenital cancer. The team of scientists headed by Professor Frank Rösl from the German Cancer Research Center (DKFZ) has now discovered that these viruses escape from immune surveillance by inactivating an important signaling molecule involved in immune responses. This hitherto unknown mechanism may yield new approaches in cancer medicine. Moreover, the molecule might also serve as a marker for detecting HPV infections before a malignant tumor develops.

About ten percent of the 170 known types of human papillomavirus are considered to be carcinogenic. HPV types 16 and 18 are particularly aggressive and belong to this group. The viruses preferentially infect cells called keratinocytes which are found in epidermal and mucosal tissues. Like herpes viruses, HPV can persist in the body for a long time. Infected cells may turn cancerous many years after the initial infection.

The project of Professor Frank Rösl and his DKFZ co-worker Dr. Bladimiro Rincon-Orozco aimed at determining how HPV manages to escape surveillance by the immune system. They focused their attention on an important immune modulator called interleukin-1beta (IL-1 β). "In healthy cells, this modulator is present as an inactive precursor called pro-IL-1 β . When a virus invades the cell, the precursor is cleaved by an enzyme into its biologically active form and released," Rösl explains. "IL-1 β attracts immune cells that finally eliminate virus-infected cells in a multistep process".

In cell culture experiments, the researchers discovered that a protein called E6, brought into cells by HPV, interferes with the process of pro-IL-1 β maturation. Bladimiro Rincon-Orozco and the PhD student Martina Niebler infected human keratinocytes with HPV-16 or HPV-18. These cells turned out to be no longer capable of releasing mature IL-1 β . The scientists discovered that this was mediated by a cellular "recycling factory" called proteasome, which normally breaks down damaged or no longer necessary proteins. E6 triggers the proteasome to eliminate pro-IL-1 β . "Degradation of the precursor molecule happens at a very early stage of the infection process. This explains why cells infected with HPV-16 or HPV-18 stop producing IL-1 β ", says Rösl. "If this signal mediator is missing, the immune system has difficulty with spotting and controlling the infection".

The investigators have shown that IL-1 β levels are not only decreased in HPV-infected cells under laboratory conditions, but also in patients. In collaboration with the Charité Berlin, they studied cervical cancer tissue samples from patients testing positive for HPV-16 or HPV-18. "The more advanced the cancer, the less IL-1 β is produced," says Bladimiro Rincon-Orozco. "Together with the Charité Berlin and Heidelberg University ("Kopfklinik"), we will now investigate whether these changes in the concentration of IL-1 β can be used as a marker for anogenital cancer and other HPV-induced cancers." These include tumors of the oropharynx, which are also linked to HPV infection.

This mechanism might also be useful for therapy: "So-called proteasome inhibitors are currently being tested in clinical trials," says Rösl. These chemical substances block the proteasome, rendering it incapable of breaking down proteins. The scientists hypothesize that if cells preserve a functional form of IL-1 β , they might restore the immune system's capability to identify and eliminate developing cancer cells.

Martina Niebler, Xu Qian, Daniela Höfler, Vlada Kogosov, Jittranan Kaewprag, Andreas M. Kaufmann, Regina Ly, Gerd Böhmer, Rainer Zawatzky, Frank Rösl, Bladimiro Rincon-Orozco. Post-Translational Control of IL-1 β via the Human Papillomavirus Type 16 E6 Oncoprotein: A Novel Mechanism of Innate Immune Escape Mediated by the E3-Ubiquitin Ligase E6-AP and p53. PLOS Pathogens. 2013 Aug 1. DOI: 10.1371/journal.ppat.1003536

A picture for this press release is available at:

www.dkfz.de/de/presse/pressemitteilungen/2013/images/Normalgewebe_und_Gebaermutterhalskrebs.jpg

Caption:

- A) Normal cervical tissue containing high levels of pro-IL1 β (stained brown)
- B) Cervical cancer, negative for pro-IL-1 β

Picture source:

DKFZ/Charité Berlin

The German Cancer Research Center (Deutsches Krebsforschungszentrum, DKFZ) with its more than 2,500 employees is the largest biomedical research institute in Germany. At DKFZ, more than 1,000 scientists investigate how cancer develops, identify cancer risk factors and endeavor to find new strategies to prevent people from getting cancer. They develop novel approaches to make tumor diagnosis more precise and treatment of cancer patients more successful. The staff of the Cancer Information Service (KID) offers information about the widespread disease of cancer for patients, their families, and the general public. Jointly with Heidelberg University Hospital, DKFZ has established the National Center for Tumor Diseases (NCT) Heidelberg, where promising approaches from cancer research are translated into the clinic. In the German Consortium for Translational Cancer Research (DKTK), one of six German Centers for Health Research, DKFZ maintains translational centers at seven university partnering sites. Combining excellent university hospitals with high-profile research at a Helmholtz Center is an important contribution to improving the chances of cancer patients. DKFZ is a member of the Helmholtz Association of National Research Centers, with ninety percent of its funding coming from the German Federal Ministry of Education and Research and the remaining ten percent from the State of Baden-Württemberg.

Dr. Stefanie Seltmann
Leiterin Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2854
F: +49 6221 42 2968
presse@dkfz.de

Dr. Sibylle Kohlstädt
Presse- und Öffentlichkeitsarbeit
Deutsches Krebsforschungszentrum
Im Neuenheimer Feld 280
D-69120 Heidelberg
T: +49 6221 42 2843
F: +49 6221 42 2968
presse@dkfz.de